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Abstract
Background: Inactivating and truncating mutations of the nuclear BRCA1-interacting protein 1
(BRIP1) have been shown to be the major cause of Fanconi anaemia and, due to subsequent
alterations of BRCA1 function, predispose to breast cancer (BC).
Methods: We investigated the effect of BRIP1 -64G>A and Pro919Ser on familial BC risk by means
of TaqMan allelic discrimination, analysing BRCA1/BRCA2 mutation-negative index patients of 571
German BC families and 712 control individuals.
Results: No significant differences in genotype frequencies between BC cases and controls for
BRIP1 -64G>A and Pro919Ser were observed.
Conclusion:  We found no effect of the putatively functional BRIP1 variants -64G>A and
Pro919Ser on the risk of familial BC.
Background
Germline mutations in the high-penetrance genes BRCA1
and BRCA2 account for up to 25% of the hereditary forms
of breast cancer (BC) [1,2]. The nuclear BRCA1-interact-
ing protein 1 (BRIP1; also referred to as BRCA1-associated
C-terminal helicase, BACH1) directly binds the BRCT-
motif containing domain of BRCA1, thus likely contribut-
ing to its DNA repair and tumour suppressor functions
[3,4]. BRIP1 deficiency has been described as the causa-
tion for cancer-predisposing Fanconi anaemia [5,6], and a
recent study has identified constitutional truncating
BRIP1 mutations to confer susceptibility to BC [7].
Several genotyping studies have addressed the association
between BRIP1 variants and BC risk, but the results have
remained controversial [8-11]. The non-conservative
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BRIP1 Pro919Ser substitition has been previously
reported to be associated with an increased BC risk up to
age 50 [12]. We evaluated the effects of BRIP -64G>A,
which may affect gene regulation, and Pro919Ser, on a
large German familial BC study cohort.
Methods
Study population
The familial breast cancer cohort comprised 571 unre-
lated German, female index cases (19 to 87 years of age;
median 45) without deleterious BRCA1 and BRCA2 muta-
tions. They were collected during the years 1996–2005
through the Institute of Human Genetics (Heidelberg,
Germany), the Department of Gynaecology and Obstet-
rics (Cologne, Germany) and the Department of Medical
Genetics (Munich, Germany). According to the German
Consortium for Hereditary Breast and Ovarian Cancer,
breast cancer cases are classified into six categories based
on family history: (A1) families with two or more breast
cancer cases including at least two cases with onset below
the age of 50 years; (A2) families with at least one male
breast cancer case; (B) families with at least one breast
cancer and one ovarian cancer case; (C) families with at
least two breast cancer cases including one case diagnosed
before the age of 50 years; (D) families with at least two
breast cancer cases diagnosed after the age of 50 years; (E)
single cases of breast cancer with age of diagnosis before
35 years [2]. All women gave written consent to the
molecular analysis of the BRCA1 and BRCA2 genes and
potential new breast cancer susceptibility genes. Prior to
DNA extraction, their blood (EDTA) was frozen at -20°C.
The DNA was isolated by a conventional phenol-chloro-
form protocol. Mutations in the open reading frame of
BRCA1 and BRCA2 were excluded by applying denaturing
high performance liquid chromatography (DHPLC) on
all exons, followed by direct sequencing of conspicuous
exons. The control series consisted of 712 healthy, unre-
lated female blood donors (26 to 68 years of age, median
49). They were recruited in 2004 and 2005 by the Institute
of Transfusion Medicine and Immunology (Mannheim,
Germany) and share the ethnic background with the
breast cancer patients. According to the German guide-
lines for blood donation, all blood donors were examined
by a standard questionnaire. Buffy coat samples were
taken from the anti-coagulated blood donations and were
used for DNA isolation (FlexiGene® DNA Kit; Qiagen,
Hilden Germany). All blood donors consented to the use
of their samples for research studies. The study was
approved by the Ethics Committee of the University of
Heidelberg (Heidelberg, Germany).
Genotyping
BRIP1 genotyping was done by the TaqMan allelic dis-
crimination method as previously described [13]. Taq-
Man primers and probes were provided by the assay-by-
design service (Applied Biosystems, Foster City, CA) and
designed on the basis of the GenBank NT_010783
sequence. Sequences of primers and probes are available
upon request.
Statistical analysis
Genotype-specific odds ratios (ORs), 95% confidence
intervals (95% CIs) and P  values were computed by
unconditional logistic regression using the Statistical
Analysis System software (Version 9.1.; SAS Institute Inc.,
Cary, NC). Haplotypes were inferred using the SNPHAP
programme created by D. Clayton [14]. Power calculation
was carried out with the power and sample size calcula-
tion software PS version 2.1.31 [15].
Transcription factor search
The search for putative transcription factors was per-
formed using TESS (Transcription Element Search Soft-
ware, [16]) and TFSEARCH (Searching Transcription
Factor Binding Sites, [17]).
Results and discussion
Mutations in the DNA helicase BRIP1 have been impli-
cated in the aetiology of Fanconi anaemia, a genetic disor-
der that is characterised by congenital abnormalities,
progressive bone marrow failure, genomic instability and
predisposition to cancer [5-7]. Our study assessed the rel-
evance of the BRIP1 variants -64G>A and Pro919Ser to
familial BC. According to transcription factor binding site
searches, the replacement of G by A at position -64 leads
to the formation of a GATA or CCAAT motif, suggesting
an modification of gene expression. BRIP Pro919Ser is
located in the BRCA1-interacting domain and may alter
protein structure and function.
Genotype frequencies for the analysed polymorphisms
were in agreement with Hardy-Weinberg expectations in
controls. No significant differences in genotype frequen-
cies between BC cases and controls for either BRIP1 -
64G>A or Pro919Ser were observed (see Table 1). Adjust-
ment for age made no significant difference to the results,
hence only unadjusted ORs are presented. Our findings
are in accord with previously published data [8,11].
Though a recent kin-cohort study has shown a strong
association with 4.5- to 6.9-fold familial BC risk for
Pro919Ser in premenopausal women [12], our data do
not support the observed effect when stratified according
to age at diagnosis (see Table 1). Haplotype analysis with
BRIP1 -64G>A and Pro919Ser did not indicate any associ-
ation with familial BC risk (data not shown).
The strengths of the present study are represented by a
sound sample size and a homogeneous study cohort of a
single ethnic group, comprising women selected for famil-
ial BC. Only BRCA1 and BRCA2 mutation-negative famil-BMC Cancer 2007, 7:83 http://www.biomedcentral.com/1471-2407/7/83
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Table 1: Genotype distributions of the BRIP1 variants -64G>A 
(rs2048718§) and Pro919Ser (rs4986764§) among unrelated 
German BRCA1/2 mutation-negative familial breast cancer 
patients and healthy, unrelated female control subjects
BRIP -64G>A CASES CONTROLS
n % n % OR* 95% CI P
All Σ 571 712
GG 181 31.7 228 32.0 1
GA 283 49.6 340 47.8 1.05 0.82–1.35 0.71
AA 107 18.7 144 20.2 0.94 0.68–1.29 0.68
GA+AA 390 68.3 484 68.0 1.02 0.80–1.29 0.90
< 50 years Σ 406 367
GG 132 32.5 113 30.8 1
GA 190 46.8 180 49.0 0.90 0.65–1.25 0.54
AA 84 20.7 74 20.2 0.97 0.65–1.45 0.89
GA+AA 274 67.5 254 69.2 0.92 0.68–1.25 0.61
50 years Σ 165 345
GG 49 29.7 115 33.3 1
GA 93 56.4 160 46.4 1.36 0.90–2.08 0.15
AA 23 13.9 70 20.3 0.77 0.43–1.37 0.38
GA+AA 116 70.3 230 66.7 1.18 0.79–1.77 0.41
BRIP 
Pro919Ser
All Σ 571 712
Pro/Pro 181 31.7 226 31.7 1
Pro/Ser 295 51.7 365 51.3 1.01 0.79–1.29 0.94
Ser/Ser 95 16.6 121 17.0 0.98 0.70–1.37 0.91
Pro/Ser+Ser/
Ser
390 68.3 486 68.3 1.00 0.79–1.27 0.97
< 50 years Σ 406 367
Pro/Pro 121 29.8 118 32.2 1
Pro/Ser 219 53.9 182 49.6 1.17 0.85–1.62 0.33
Ser/Ser 66 16.3 67 18.3 0.96 0.63–1.47 0.85
Pro/Ser+Ser/
Ser
285 70.2 249 67.8 1.12 0.82–1.51 0.48
50 years Σ 165 345
Pro/Pro 60 36.4 108 31.3 1
Pro/Ser 76 46.1 183 53.0 0.75 0.49–1.13 0.17
Ser/Ser 29 17.6 54 15.7 0.97 0.56–1.68 0.90
Pro/Ser+Ser/
Ser
105 63.6 237 68.7 0.80 0.54–1.18 0.26
*As compared to GG and Pro/Pro homozygotes, respectively; § 
dbSNP rs#; Hardy-Weinberg equilibrium test was undertaken using 
Pearson's goodness-of-fit chi-square test with one degree of 
freedom. Adjustment for age did not change the ORs, assuming that 
the distribution of the BRIP1 genotypes is age-independent.
ial BC cases were considered in order to avoid effects
caused by these high-penetrance susceptibility genes.
With the present sample size, we had a power of 80% at a
significance level of 0.05 to detect an OR of ≥ 1.44 for
both -64G>A and Pro919Ser. Moreover, the power of an
association study based on cases with a family history of
the disease is at least twice higher compared to a study
using unselected cases [14]. As data of well-known risk
factors (age of menarche, history of pregnancy etc.) were
not available, we ignored to test for gene-environment
interaction.
Conclusion
Both the BRIP1 -64G>A and Pro919Ser variants show no
effect on familial BC risk in the German population.
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